VIDEO: A spotlight on treatment options for mild to moderate UC, Crohn’s disease
Click Here to Manage Email Alerts
NAPLES, Florida — Jennifer L. Seminerio, MD, spoke with Healio about key takeaways from her 2022 ACG/FGS Spring Symposium presentation, which focused on treatment for mild to moderate ulcerative colitis and Crohn’s disease.
“One of the take-home points that we really are trying to home in on is position drug therapy in these disease states,” Seminerio, assistant professor and director of the Inflammatory Bowel Disease Center at the University of South Florida, said. “When you’re talking about ulcerative colitis, specifically, and you’re in the mild to moderate disease states, it’s important to categorize which one you’re dealing with using severity index scores and endoscopic scores. From there, coming up with a discussion with your patient on where they want to see their drug therapies go.”
Seminerio discussed multiple treatment options for UC patients, including mesalamines, steroids, immunosuppressive agents and biologics, and explained that although mesalamines are not indicated for patients with CD, the other therapies are options for these patients depending on their disease state.
“Unfortunately, in Crohn’s disease, we don’t quite have the oral small molecules yet, but that’s the future that we’re looking forward to,” Seminerio said.
Collapse
Click Here to Manage Email Alerts